Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX) announced a corporate update and financial results for Q1 2022 set for May 9, 2022, post-market close. The management will share a video highlighting business and pipeline progress, followed by a live Q&A at 4:30 p.m. ET. Praxis is focused on developing therapies for CNS disorders linked to neuronal imbalances and boasts a broad portfolio, including multiple clinical-stage product candidates addressing various neurological and psychiatric disorders. For more, visit Praxis Medicines.

Praxis Precision Medicines hosted its 2022 Epilepsy Day in New York City, showcasing its advancements in treating CNS disorders. CEO Marcio Souza highlighted their innovative approaches and significant progress across three major epilepsy programs: PRAX-222, PRAX-562, and PRAX-628, all expected to reach clinical stages by the end of 2022. The company aims to address unmet needs in epilepsy management with targeted therapies. This event emphasized Praxis' multi-billion-dollar market opportunity in the epilepsy sector, reflecting its commitment to rapid drug development driven by genetic insights.

Praxis Precision Medicines (NASDAQ: PRAX) has announced an upcoming Epilepsy Day on April 27, 2022, from 8:30 a.m. to 11:30 a.m. ET, held virtually and in New York City. This event will highlight the company's extensive epilepsy pipeline, the largest in the industry, and discuss clinical and regulatory strategies. Key opinion leaders like Dr. Jacqueline French and Dr. Daniel Friedman will share insights on advancements in epilepsy and unmet patient needs. A live webcast will be available on their website, with a replay accessible for 90 days.

Praxis Precision Medicines (NASDAQ: PRAX) has announced that data from its PRAX-944 essential tremor (ET) program will be showcased at the 2022 American Academy of Neurology Annual Meeting in Seattle from April 2-7, and virtually from April 24-26. Chief Medical Officer Bernard Ravina highlighted the need for better therapeutic options for ET, as current treatments often have poor tolerability. PRAX-944, a T-type calcium channel blocker, has shown promise in reducing tremor symptoms with acceptable safety profiles. The oral presentation is scheduled for April 6 at 5:06 PM PT.

Praxis Precision Medicines (NASDAQ: PRAX) announced its participation in a fireside chat at Stifel’s 4th Annual CNS Day on March 29, 2022, at 11:30 a.m. ET. The event will be accessible through a live webcast on the company’s website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders by leveraging genetic insights into neuronal excitation-inhibition imbalances, targeting both rare and prevalent neurological and psychiatric conditions. For more details, visit www.praxismedicines.com.

Praxis Precision Medicines (NASDAQ: PRAX) will participate in the Neuropsych panel at Cowen’s 42^nd Annual Healthcare Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Praxis focuses on developing therapies for CNS disorders using genetic insights, addressing conditions such as epilepsy, psychiatric, and movement disorders. They currently have three clinical-stage product candidates.

Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and reported financial results for Q4 and full year 2021. The company expects topline results for PRAX-114 Phase 2/3 Aria Study for Major Depressive Disorder in June 2022. As of December 31, 2021, Praxis had $275.9 million in cash, funding operations into Q2 2023. R&D expenses rose to $120.3 million for 2021, up from $45 million in 2020. Net loss for 2021 was $167.1 million, compared to $61.8 million the previous year. Upcoming milestones include multiple study results for psychiatric and movement disorders.

Praxis Precision Medicines (NASDAQ: PRAX) announced on February 22, 2022, that it will release its fourth quarter and full year 2021 financial results on February 28, 2022, prior to U.S. market opening. The company will provide a corporate update and report on recent business and pipeline advancements through a video presentation. Afterward, a live Q&A session will be held at 8:30 a.m. ET. Praxis focuses on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, with three clinical-stage product candidates.

Praxis Precision Medicines (NASDAQ: PRAX) announced positive results from a preclinical study of PRAX-562, a new sodium channel blocker targeting rare Developmental and Epileptic Encephalopathies (DEEs). The study showed robust antiseizure activity and improved tolerability compared to existing therapies. Praxis plans to initiate a Phase 2 trial in Q1 2022 for treating DEEs, supported by favorable data presented at the American Epilepsy Society Annual Meeting. PRAX-562 has received Orphan Drug Designation from the FDA, indicating its potential as a viable treatment for epilepsy.